FrancophonIA/ELRC3.0 huggingface dataset:
English: Separate preparations of emtricitabine and tenofovir disoproxil are available for treatment of HIV-1 infection if it becomes necessary to discontinue or modify the dose of one of the components of Emtricitabine/Tenofovir disoproxil Zentiva.
Maltese: Preparazzjonijiet separati ta' emtricitabine u tenofovir disoproxil huma disponibbli għat-trattament talinfezzjoni tal-HIV 1 jekk ikun meħtieġ li titwaqqaf jew tiġi modifikata d-doża ta' wieħed millkomponenti ta' Emtricitabine/Tenofovir disoproxil Zentiva.
English: The apparent clearance of tenofovir averaged approximately 307 ml/min.
Maltese: It-tneħħija apparenti ta' tenofovir kellha medja ta' madwar 307 mL/min.
English: In 2 of 14 subjects who had acute HIV infection at study enrollment, the K65R mutation was detected in the HIV of 1 of 5 subjects in the tenofovir disoproxil 245 mg group and the M184V mutation (associated with resistance to emtricitabine) was detected in the HIV of 1 of 3 subjects in the emtricitabine/tenofovir disoproxil group.
Maltese: Fi 2 minn 14-il individwu li kellhom infezzjoni akuta tal-HIV meta rreġistraw mal-istudju, il-mutazzjoni K65R kienet skoperta fl-HIV ta' 1 minn 5 individwi fil-grupp ta' tenofovir disoproxil 245 mg u lmutazzjoni M184V (assoċjata mar-reżistenza għal emtricitabine) kienet skoperta fl-HIV ta' 1 minn 3 suġġetti fil-grupp ta' emtricitabine/tenofovir disoproxil.
English: Prevention of HIV in adults and adolescents aged 12 years and older, weighing at least 35 kg One tablet, once daily.
Maltese: Prevenzjoni tal-HIV fl-adulti u adolexxenti li għandhom 12-il sena u aktar, u li jiżnu tal-anqas 35 kg Pillola waħda, darba kuljum.
English: PC: [outer packaging only] SN: [outer packaging only] NN: [outer packaging only]
Maltese: IDENTIFIKATUR UNIKU - DATA LI TINQARA MILL-BNIEDEM PC: [għall-pakkett ta' barra]
English: Outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 90 (3 bottles of 30) film-coated tablets.
Maltese: Il-kartun ta' barra li fihom flixkun wieħed ta'30 pillola miksija b'rita u kartun ta' barra li fihom flixkun wieħed ta' 90 (3 fliexken ta' 30) pillola miksija b'rita.
English: If serum phosphate is < 1.5 mg/dl (0.48 mmol/l) or creatinine clearance is decreased to < 60 ml/min in any individual receiving Emtricitabine/Tenofovir disoproxil Zentiva for pre-exposure prophylaxis, renal function should be re evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Maltese: Jekk il-phosphate fis-serum huwa < 1.5 mg/dL (0.48 mmol/L) jew it-tneħħija tal-kreatinina tonqos għal < 50 mL/min fi kwalunkwe pazjent li jingħata Emtricitabine/tenofovir disoproxil , il-funzjoni talkliewi għandha tiġi evalwata mill-ġdid fi żmien ġimgħa, inkluż il-kejl tal-konċentrazzjonijiet talglukożju fid-demm, il-potassium fid-demm u l-glukożju fl-awrina (ara sezzjoni 4.8, tubulopatija prossimali).
English: AUC: ↓ 9% (↓ 16 to ↓ 1) Cmax: ↓ 7% (↓ 22 to ↑ 11)
Maltese: AUC: ↓ 9% (↓ 16 sa ↓ 1) Cmax: ↓ 7% (↓ 22 sa ↑ 11) Cmin: NC
English: The pharmacokinetics of emtricitabine / tenofovir disoproxil have not been studied in subjects with hepatic impairment.
Maltese: Il-farmakokinetiċi ta' emtricitabine / tenofovir disoproxil ma ġewx studjati f'individwi b'indeboliment epatiku.
English: Emtricitabine and tenofovir are eliminated by renal excretion and the exposure to emtricitabine and tenofovir increases in individuals with renal dysfunction (see sections 4.4 and 5.2).
Maltese: Indeboliment renaliEmtricitabine u tenofovir huma eliminati permezz ta' tneħħija renali u lesponiment għal emtricitabine u tenofovir tiżdied f'individwi b'disfunzjoni renali (ara sezzjonijiet 4.4 u 5.2).
English: + raltegravir (400 mg b.i.d) + emtricitabine/tenofovir disoproxil (200 mg/245 mg q.d.)
Maltese: (800 mg q.d.) + Ritonavir (100 mg q.d.) + Emtricitabine/Tenofovir disoproxil (200 mg/245 mg q.d.)
English: What Emtricitabine/Tenofovir disoproxil Zentiva is and what it is used for Emtricitabine/Tenofovir disoproxil Zentiva contains two active substances, emtricitabine and tenofovir disoproxil.
Maltese: Emtricitabine/Tenofovir disoproxil Zentiva fih żewġ sustanzi attivi, emtricitabine u tenofovir disoproxil.
English: AUC: ↔ Cmax: ↓ 30%
Maltese: AUC: ↔ Cmax: ↓ 30% Cmin: N/A
English: • That there is an increased risk of renal disease in HIV infected patients associated with tenofovir disoproxil-containing products such as Emtricitabine/Tenofovir disoproxil Zentiva
Maltese: • Li hemm riskju miżjud ta' mard tal-kliewi f'pazjenti infettati bl-HIV assoċjat ma' prodotti li fihom Emtricitabine/Tenofovir disoproxil Zentiva
English: Emtricitabine/Tenofovir disoproxil Zentiva contains sodium
Maltese: Tiħux Emtricitabine/Tenofovir disoproxil Zentiva biex tittratta
English: Furthermore, in a small clinical study, a subgroup of patients with creatinine clearance between 50 and 60 ml/min who received tenofovir disoproxil in combination with emtricitabine every 24 hours had a 2-4-fold higher exposure to tenofovir and worsening of renal function (see section 5.2).
Maltese: Barra dan, fi studju kliniku żgħir, sottogrupp ta' pazjenti bi tneħħija ta' kreatinina ta' bejn 50 u 60 mL/min li rċevew tenofovir disoproxil flimkien ma' emtricitabine kull 24 siegħa kellhom esponiment 2 4 darbiet ogħla għal tenofovir u aggravament tal-funzjoni tal-kliewi (ara sezzjoni 5.2).
English: FTC/tenofovir disoproxil groupa
Maltese: Grupp tal-FTC/tenofovir disoproxila
English: Adefovir dipivoxil and Emtricitabine/Tenofovir disoproxil Zentiva should not be administered concomitantly (see section 4.4).
Maltese: Adefovir dipivoxil u Emtricitabine/Tenofovir disoproxil Zentiva ma għandhomx jingħataw flistess ħin (ara sezzjoni 4.4).
English: Since emtricitabine and tenofovir are primarily eliminated by the kidneys, co-administration of Emtricitabine/Tenofovir disoproxil Zentiva with medicinal products that reduce renal function or compete for active tubular secretion (e.g. cidofovir) may increase serum concentrations of emtricitabine, tenofovir and/or the co-administered medicinal products.
Maltese: Prodotti mediċinali eliminati mill-kliewiMinħabba li emtricitabine u tenofovir huma primarjament eliminati mill-kliewi, l-għoti ta' Emtricitabine/Tenofovir disoproxil Zentiva flimkien ma' prodotti mediċinali li jnaqqsu l-funzjoni tal-kliewi jew jikkompetu għas-sekrezzjoni tubulari attiva (eż. cidofovir) jista' jżid il-konċentrazzjonijiet fis-serum ta' emtricitabine, tenofovir u/jew il-prodotti mediċinali li jingħataw flimkien.
English: Individuals over the age of 65 years are more likely to have decreased renal function, therefore caution should be exercised when administering Emtricitabine/Tenofovir disoproxil Zentiva to older people.
Maltese: Individwi li għandhom iżjed minn 65 sena huma aktar probabbli li jkollhom tnaqqis tal-funzjoni renali, għalhekk għandha tingħata attenzjoni partikulari meta Emtricitabine/Tenofovir disoproxil Zentiva jingħata lil persuni anzjani.
English: AUC: ↓ 4% (↓ 9 to ↑ 0) Cmax: ↓ 6% (↓ 13 to ↑ 0) Cmin: ↓ 2% (↓ 9 to ↑ 6)
Maltese: AUC: ↓ 4% (↓ 9 sa ↑ 0) Cmax: ↓ 6% (↓ 13 sa ↑ 0)
English: Discontinuation of Emtricitabine/Tenofovir disoproxil Zentiva therapy in patients infected with HBV may be associated with severe acute exacerbations of hepatitis.
Maltese: It-twaqqif tat-terapija b'Emtricitabine/tenofovir disoproxil Zentiva f'pazjenti infettati bl-HBV jista' jkun assoċjat ma' aggravamenti akuti severi tal-epatite.
English: Cmin: ↑ 42% (↑ 34 to ↑ 49) Atazanavir:
Maltese: Cmin: ↑ 42% (↑ 34 għal ↑ 49)
English: Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil, sofosbuvir/velpatasvir/voxilaprevir and darunavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Maltese: Żieda fil-konċentrazzjonijiet ta' tenofovir fil-plażma li tirriżulta millgħoti fl-istess ħin ta' tenofovir disoproxil, sofosbuvir/velpatasvir/voxilaprevir u darunavir/ritonavir tista' żżid irreazzjonijiet avversi relatati ma' tenofovir disoproxil, li jinkludu disturbi renali.
English: Seven patients had estimated glomerular filtration rate (GFR) values between 70 and 90 ml/min/1.73 m2.
Maltese: Seba' pazjenti kellhom valuri stmati tar-rata ta' filtrazzjoni glomerulari (GFR - glomerular filtration rate) ta' bejn 70 u 90 mL/min/1.73 m2. Fost dawn, 3 pazjenti esperjenzaw tnaqqis klinikament sinifikanti fil-GFR stmat waqt it-terapija li tjieb wara li tenofovir disoproxil twaqqaf.
English: Cmax: ↑ 77% (↑ 53 to ↑ 104) Cmin: ↑ 121% (↑ 100 to ↑ 143)
Maltese: Cmax: ↑ 55% (↑ 41 sa ↑ 71) Cmin: ↑ 301% (↑ 257 sa
English: • If you take Emtricitabine/Tenofovir disoproxil Zentiva for treatment of HIV infection, stopping tablets may reduce the effectiveness of the anti-HIV therapy recommended by your doctor.
Maltese: • Jekk tieħu Emtricitabine/Tenofovir disoproxil Zentiva għat-trattament ta' infezzjoni tal-HIV, ittwaqqif tal-pilloli jista' jnaqqas l-effettività tat-terapija ta' kontra l-HIV rakkomandata mit-tabib tiegħek.
English: HIV-1 infected patients receiving Emtricitabine/Tenofovir disoproxil Zentiva or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.
Maltese: Pazjenti infettati bl-HIV-1 li jirċievu Emtricitabine/Tenofovir disoproxil Zentiva jew kwalunkwe terapija antiretrovirali oħra jistgħu jkomplu jiżviluppaw infezzjonijiet opportunistiċi u kumplikazzjonijiet oħra tal-infezzjoni tal-HIV, u għalhekk għandhom jibqgħu taħt osservazzjoni klinika mill-qrib minn tobba esperjenzati fit-trattament ta' pazjenti b'mard assoċjat mal-HIV.
English: + darunavir/ritonavir (800 mg q.d./100 mg q.d.)
Maltese: Ledipasvir/sofosbuvir (90 mg/400 mg q.d.) + darunavir/ritonavir (800 mg q.d./100 mg q.d.) +
English: Table 1: Dosing recommendations in adults with renal impairment Treatment of HIV-1 infection Pre-exposure prophylaxis
Maltese: Tabella 1: Dożi rakkomandati f'adulti b'indeboliment tal-kliewi
English: • dizziness, headache,
Maltese: • uġigħ, uġigħ fl-istonku,
English: HIV-1 uninfected individuals should be counselled at frequent intervals to strictly adhere to the recommended Emtricitabine/Tenofovir disoproxil Zentiva daily dosing schedule.
Maltese: Individwi mhux infettati bl-HIV-1 għandhom jingħataw parir f'intervalli frekwenti biex jaderixxu b'mod strett mal-iskeda ta' dożaġġ ta' kuljum rakkomandata ta' Emtricitabine/Tenofovir disoproxil Zentiva.
English: Cmax: ↑ 64% (↑ 54 to ↑ 74) Cmin: ↑ 59% (↑ 49 to ↑ 70)
Maltese: Cmin: ↑ 59% (↑ 49 għal ↑ 70)
English: Secondary efficacy analyses over 144 weeks included the proportion of patients with HIV-1 RNA concentrations < 400 or < 50 copies/ml, and change from baseline in CD4 cell count.
Maltese: Lanaliżi ta' l-effikaċja sekondarja fuq perjodu ta' 144 ġimgħa kienet tinkludi l-proporzjon ta' pazjenti b'konċentrazzjonijiet tal-RNA tal-HIV 1 ta' < 400 jew < 50 kopja/ml, u l bidla mil-linja bażi fl-għadd taċ-ċelluli tas-CD4.
English: Recommendation concerning co-administration with Emtricitabine/Tenofovir disoproxil Zentiva (emtricitabine 200 mg, tenofovir disoproxil 245 mg)
Maltese: Rakkomandazzjoni dwar l-għoti flimkien ma' Emtricitabine/Tenofovir disoproxil Zentiva (emtricitabine 200 mg, tenofovir disoproxil 245 mg)
English: Co-administration of Emtricitabine/Tenofovir disoproxil Zentiva and didanosine is not recommended (see section 4.4).
Maltese: L-għoti ta' Emtricitabine/Tenofovir disoproxil Zentiva flimkien ma' didanosine mhuwiex rakkomandat (ara sezzjoni 4.4).
English: Emtricitabine/Tenofovir disoproxil Zentiva can only help reduce your risk of getting HIV before you are infected.
Maltese: Emtricitabine/Tenofovir disoproxil Zentiva jista' jgħin biss inaqqas ir-riskju tiegħek li tieħu l-HIV qabel tiġi infettat.
English: Outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 3 bottles of 30 film-coated tablets.
Maltese: Kartun ta' barra li fihom flixkun 1 ta' 30 pillola miksijin b'rita u kartun ta' barra li fihom 3 fliexken ta' 30 pillola miksijin b'rita.
English: Comparisons for active study groups are made versus placebo.
Maltese: It-tqabbil għall-gruppi tal-istudju attivi sar kontra plaċebo.
English: Emtricitabine/Tenofovir disoproxil Zentiva should only be used for pre-exposure prophylaxis as part of an overall HIV-1 infection prevention strategy including the use of other HIV-1 prevention measures (e.g. consistent and correct condom use, knowledge of HIV-1 status, regular testing for other sexually transmitted infections).
Maltese: Emtricitabine/Tenofovir disoproxil Zentiva għandu jintuża biss għal profilassi ta' qabel l-esponiment bħala parti minn strateġija globali għall-prevenzjoni tal-infezzjoni tal-HIV-1 li tinkludi l-użu ta' miżuri ta' prevenzjoni oħrajn tal-HIV-1 (eż. l-użu konsistenti u korrett ta' kondoms, l-għarfien tal-istat talHIV-1, l-ittestjar regolari għal infezzjonijiet oħra trasmessi sesswalment).
English: The bone toxicity in young adult rats and dogs occurred at exposures ≥ 5-fold the exposure in paediatric or adult patients; bone toxicity occurred in juvenile infected monkeys at very high exposures following subcutaneous dosing (≥ 40-fold the exposure in patients).
Maltese: It-tossiċità fl-għadam f'firien u klieb adulti żgħażagħ seħħet f'esponimenti li kienu ≥ 5 darbiet iżjed mill-esponiment f'pazjenti pedjatriċi jew adulti; it-tossiċità flgħadam seħħet f'xadini ġuvenili infettati b'esponimenti għoljin ħafna wara dożaġġ taħt il-ġilda (≥ 40 darba iżjed mill-esponiment fil-pazjenti).
English: Renal management in HIV-1 infected patients
Maltese: Trattament għal infezzjoni tal-HIV-1
English: Emtricitabine/Tenofovir disoproxil Zentiva alone does not constitute a complete regimen for the treatment of HIV-1 and HIV-1 resistance mutations have emerged in individuals with undetected HIV-1 infection who are only taking Emtricitabine/Tenofovir disoproxil Zentiva.
Maltese: Emtricitabine/Tenofovir disoproxil Zentiva waħdu mhux kors komplut għat-trattament tal-HIV-1 u mutazzjonijiet ta' reżistenza tal-HIV-1 feġġew f'individwi b'infezzjoni tal-HIV-1 mhux skoperta li jkunu qed jieħdu Emtricitabine/Tenofovir disoproxil Zentiva waħdu.
English: If clinical symptoms consistent with acute viral infection are present and recent (< 1 month) exposures to HIV-1 are suspected, use of Emtricitabine/Tenofovir disoproxil Zentiva should be delayed for at least one month and HIV-1 status reconfirmed before starting Emtricitabine/Tenofovir disoproxil Zentiva for pre-exposure prophylaxis.
Maltese: Jekk ikun hemm preżenti sintomi kliniċi konsistenti ma' infezzjoni virali akuta u huma ssuspettati esponimenti riċenti (< 1 xahar) għall-HIV-1, l-użu ta' Emtricitabine/Tenofovir disoproxil Zentiva għandu jiġi ttardjat mill-inqas għal xahar u l-istat tal-HIV-1 ikkonfermat mill-ġdid qabel ma Emtricitabine/Tenofovir disoproxil Zentiva jinbeda għal profilassi ta' qabel l-esponiment.
English: Co-administration of tenofovir disoproxil and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosinerelated adverse reactions.
Maltese: L-għoti ta' tenofovir disoproxil flimkien ma' didanosine jirriżulta f'żieda ta' 40 60% fl-esponiment sistemiku għad-didanosine, li jista' jżid ir-riskju għal reazzjonijiet avversi relatati ma' didanosine.
English: The pharmacokinetics of emtricitabine have not been studied in non-HBV infected subjects with varying degrees of hepatic insufficiency.
Maltese: Il-farmakokinetika ta' emtricitabine ma ġewx studjata f'individwi li m'humiex infettati bl-HBV, bi gradi diversi ta' insuffiċjenza epatika.
English: Treatment of HIV-1 infection
Maltese: Trattament tal-infezzjoni bl-HIV-1
English: Mean change from baseline in CD4 cell count (cells/mm3) p-value
Maltese: Bidla medja mil-linja bażi flgħadd taċ-ċelluli CD4 (ċelluli/mm3)
English: ANTI-INFECTIVES Antiretrovirals
Maltese: Disturbi gastro-intestinali
English: Before taking Emtricitabine/Tenofovir disoproxil Zentiva to reduce the risk of getting HIV:
Maltese: Qabel tieħu Emtricitabine/Tenofovir disoproxil Zentiva biex tnaqqas ir-riskju li tieħu l-HIV:
English: • HIV paediatric renal educational brochure
Maltese: • Opuskolu edukattiv dwar il-kliewi u l-HIV fit-tfal
English: Patients at risk of renal impairment (such as patients with baseline renal risk factors, advanced HIV disease, or patients receiving concomitant nephrotoxic medications) are at increased risk of experiencing incomplete recovery of renal function despite tenofovir disoproxil discontinuation (see section 4.4).
Maltese: Pazjenti f'riskju ta' indeboliment renali (bħal pazjenti b'fatturi ta' riskju renali fil-linja bażi, mard ta' l-HIV li jkun fi stadju avvanzat, jew pazjenti li jkunu qed jirċievu prodotti mediċinali nefrotossiċi fl-istess ħin) ghandhom riskju akbar li jkollhom irkupru mhux komplet tal-funzjoni renali minkejja t- twaqqif ta' tenofovir disoproxil (ara sezzjoni 4.4).
English: Cmax: ↑ 47% (↑ 37 to ↑ 58) Cmin: ↑ 47% (↑ 38 to ↑ 57)
Maltese: Cmin: ↑ 47% (↑ 38 għal ↑
English: • decreases in phosphate in the blood,
Maltese: • tnaqqis fil-phosphate fid-demm,
English: Co-administration of tenofovir disoproxil and didanosine is not recommended as it results in a 40 - 60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Maltese: L-għoti ta' tenofovir disoproxil flimkien ma' didanosine mhuwiex rakkomandat għax jista' jirriżulta f'żieda ta' 40 60% fl-esponiment sistemiku għal didanosine li jista' jżid ir-riskju għal reazzjonijiet avversi relatati ma' didanosine (ara sezzjoni 4.5).
English: While taking Emtricitabine/Tenofovir disoproxil Zentiva you may still develop infections or other illnesses associated with HIV infection.
Maltese: Emtricitabine/Tenofovir disoproxil Zentiva għandu jinbeda minn tabib b'esperjenza fl-immaniġġjar ta' infezzjoni HIV.
English: Patients infected with HBV who discontinue Emtricitabine/Tenofovir disoproxil Zentiva should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.
Maltese: Pazjenti infettati bl-HBV li jwaqqfu Emtricitabine/tenofovir disoproxil Zentiva għandhom jiġu mmonitorjati mill-qrib b'segwitu kemm kliniku kif ukoll tal-laboratorju mill-inqas għal diversi xhur wara li jitwaqqaf it-trattament.
English: BMD Z-scores declined by -0.012 for lumbar spine and by -0.338 for total body in the 64 subjects who were treated with tenofovir disoproxil for 96 weeks.
Maltese: 338 għall-ġisem kollu fl-64 individwu li ġew ittrattati b'tenofovir disoproxil għal 96 ġimgħa.
English: As Emtricitabine/Tenofovir disoproxil Zentiva contains emtricitabine and tenofovir disoproxil, any interactions that have been identified with these agents individually may occur with Emtricitabine/Tenofovir disoproxil Zentiva.
Maltese: Minħabba li Emtricitabine/Tenofovir disoproxil Zentiva fih emtricitabine u tenofovir disoproxil, kull interazzjoni li ġiet identifikata ma' dawn is-sustanzi individwalment tista' sseħħ b'Emtricitabine/Tenofovir disoproxil Zentiva.
English: Emtricitabine/Tenofovir disoproxil Zentiva should not be given to adolescents with existing kidney problems.
Maltese: Emtricitabine/Tenofovir disoproxil Zentiva m'għandux jingħata lil adolexxenti bi problemi eżistenti tal-kliewi.
English: Do not stop taking Emtricitabine/Tenofovir disoproxil Zentiva
Maltese: X'fih Emtricitabine/Tenofovir disoproxil Zentiva
English: • Although there are limited clinical data on the use of Emtricitabine/Tenofovir disoproxil Zentiva in pregnant women, it is not usually used unless absolutely necessary.
Maltese: • Għalkemm hemm dejta klinika limitata dwar l-użu ta' Emtricitabine/Tenofovir disoproxil Zentiva f'nisa tqal, dan normalment ma jintużax jekk mhux assolutament meħtieġ.
English: • inflammation of the kidney, passing a lot of urine and feeling thirsty, kidney failure, damage to kidney tubule cells.
Maltese: • infjammazzjoni tal-kliewi, tgħaddi ħafna awrina u tħossok bil-għatx, falliment tal-kliewi, ħsara liċ ċelluli tubuli tal-kliewi.
English: The increased dose interval for emtricitabine/tenofovir disoproxil in HIV-1 infected patients with moderate renal impairment is expected to result in higher peak plasma concentrations and lower Cmin levels as compared to patients with normal renal function.
Maltese: Iż-żieda fl-intervall tad-dożaġġ ta' emtricitabine / tenofovir disoproxil f'pazjenti bl-HIV-1 b'indeboliment renali moderata huma mistennija li tirriżulta f'livelli ogħla tal-konċentrazzjonijiet massimi fil-plażma u livelli aktar baxxi ta' Cmin meta mqabbla ma' pazjenti b'funzjoni renali normali.
English: • If you are taking Emtricitabine/Tenofovir disoproxil Zentiva to reduce the risk of getting HIV, take Emtricitabine/Tenofovir disoproxil Zentiva every day, not just when you think you have been at risk of HIV infection.
Maltese: • Jekk inti qed tieħu Emtricitabine/Tenofovir disoproxil Zentiva biex tnaqqas ir-riskju li tieħu lHIV, ħu Emtricitabine/Tenofovir disoproxil Zentiva kuljum, mhux biss meta taħseb li kont f'riskju li tieħu infezzjoni tal-HIV.
English: Seroconversions / Na Incidence per 100 person-years (95% CI) 1.99 (1.49, 2.62) Relative Risk Reduction (95% CI) a Relative risk reduction calculated for mITT cohort based on incident (post-baseline) seroconversion.
Maltese: Inċidenza kull 100 snin ta' persuna (95% CI) Tnaqqis fir-Riskju Relattiv (95% CI)
English: What you need to know before you take Emtricitabine/Tenofovir disoproxil Zentiva Do not take Emtricitabine/Tenofovir disoproxil Zentiva to treat HIV or to reduce the risk of getting HIV if you are allergic to emtricitabine, tenofovir, tenofovir disoproxil or any of the other ingredients of this medicine (listed in section 6).
Maltese: HIV jew biex tnaqqas ir-riskju li tieħu HIV jekk inti allerġiku għal emtricitabine, tenofovir, tenofovir disoproxil jew għal xi sustanza oħra ta' din il-mediċina (imniżżla fis-sezzjoni 6).
English: Indication'
Maltese: TIKKETTAR
English: ** The p-value based on the Cochran-Mantel-Haenszel Test stratified for baseline CD4 cell count.
Maltese: • It-tfal komunement kellhom għadd baxx taċ-ċelluli ħomor tad-demm (anemija).
English: • If you are being treated for HIV infection, your doctor will prescribe Emtricitabine/Tenofovir disoproxil Zentiva with other antiretroviral medicines.
Maltese: • Jekk qed tiġi ttrattat għall-infezzjoni tal-HIV, it-tabib tiegħek ser jippreskrivi Emtricitabine/Tenofovir disoproxil Zentiva ma' mediċini antiretrovirali oħra.
English: Emtricitabine/tenofovir disoproxil has not been studied in HIV-1 uninfected individuals with creatinine clearance < 60 ml/min and is therefore not recommended for use in this population.
Maltese: Ġestjoni tal-kliewi fi profilassi ta' qabel l-esponiment Emtricitabine/tenofovir disoproxil ma ġiex studjat f'individwi mhux infettati bl-HIV-1 bi tneħħija talkreatinina ta' < 60 mL/min u għalhekk mhux rakkomandat għall-użu f'din il-popolazzjoni.
English: If renal abnormalities are suspected or detected then consultation with a nephrologist should be obtained to consider interruption of Emtricitabine/Tenofovir disoproxil Zentiva use.
Maltese: Jekk anormalitajiet renali huma suspettati jew osservati, allura konsultazzjoni ma' nefroloġista għandha tiġi kkunsidrata għall-waqfien tal-użu ta' Emtricitabine/Tenofovir disoproxil Zentiva.
English: Emtricitabine/Tenofovir disoproxil Zentiva with food and drink
Maltese: Emtricitabine/Tenofovir disoproxil Zentiva għal PrEP f'adulti u adolexxenti
English: • Know your hepatitis B virus (HBV) infection status before starting Emtricitabine/Tenofovir disoproxil Zentiva.
Maltese: • Kun af l-istat tiegħek tal-infezzjoni bil-virus tal-epatite B (HBV) tiegħek, qabel tibda f'Emtricitabine/Tenofovir disoproxil Zentiva
English: Only samples from subjects randomized to emtricitabine/tenofovir disoproxil were evaluated for detectable plasma or intracellular tenofovir disoproxil-DP levels.
Maltese: Huma biss il-kampjuni minn individwi magħżula b'mod każwali għal emtricitabine/tenofovir disoproxil li kienu evalwati għal livelli misjuba ta' tenofovir disoproxil-DP fil-plażma jew intraċellulari.